Lasa Supergenerics Limited — Important, 28-01-2025: General Updates

In a recent board meeting, Lasa Supergenerics Limited approved the issuance of 2,500,000 warrants, each convertible into one fully paid-up equity share at a face value of ₹10, on a preferential basis, subject to regulatory and shareholder approval. Consequently, an Extraordinary General Meeting (EGM) is scheduled to gather shareholder consent for this move. The company also approved a rights issue of equity shares, aiming to raise up to ₹49 crores for existing shareholders, the exact terms of which will be detailed later following necessary approvals.

Post-issue, the promoter group's shareholding is expected to increase from 53.65% to 55.85%, indicating a stronger control. These capital-raising efforts may enhance financial flexibility and position Lasa for future growth opportunities. Investors should watch closely for the EGM's outcome and the refining of the rights issue terms, which could lead to potential gains in equity value.